Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference
Theorist position for analysis SDA-2026-04-28-microglial-priming-causal-nd: Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference
Context: Analytic arms: cell-type-specific MR, scVelo trajectory, longitudinal CSF Granger causality. Exposure genes: TREM2, CX3CR1, C1QA, C1QB, C1QC. Diseases: AD, PD, ALS, MS.
Primary claim: microglial priming as a partially upstream causal node rather than a pure disease-stage correlate is a debate-worthy mechanism or quality claim, not just a restatement of the analysis title. The strongest version predicts a proximal readout that changes before a late outcome. For this causal inference analysis, the debate should preserve the named strata and entities: TREM2, CX3CR1, C1QA, C1QB, C1QC.
The constructive hypothesis is that the analysis can advance SciDEX's world model if it binds the question to a falsifier. The priority test is triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses. A positive result would require concordant movement of the proximal readout and a disease-relevant or reproducibility-relevant endpoint; a negative result would downgrade the claim rather than merely mark the analysis as inconclusive.
For the downstream Atlas and Exchange layers, the useful artifact is a debated hypothesis with explicit evidence requirements, not a generic confidence score. The claim should therefore carry a clear action: validate the mechanism, strengthen the benchmark, or revise the preregistered target based on the specified falsifier.
Skeptic critique for analysis SDA-2026-04-28-microglial-priming-causal-nd: Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: microglial activation can be both cause and response; weak eQTL instruments, cell-state drift, and disease-stage confounding could inflate upstream causal estimates.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across TREM2, CX3CR1, C1QA, C1QB, C1QC. Third, an analysis that lacks provenance, environment capture, or preregistered endpoints can produce plausible but non-reproducible conclusions.
A decisive falsifier would be failure of triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses to move the predicted proximal endpoint under adequate power and controls. The strongest alternative explanation is that the observed signal is a disease-stage marker, prompt or notebook artifact, or compensatory response rather than an upstream driver.
Domain expert assessment for analysis SDA-2026-04-28-microglial-priming-causal-nd: Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference
The practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence intervals, a notebook reproducibility badge, or a revised preregistration.
Feasibility is moderate because the question is specific enough to test, but the intervention point may be less direct than the named entity. For therapeutic claims, safety and timing matter; for benchmark and methodology claims, calibration, reproducibility, and leakage controls matter. The near-term deliverable should be a falsifiable validation plan rather than a premature declaration of success.
Consensus is strongest around using this analysis to sharpen the world model. Dissent remains around causal direction, artifact robustness, and translational tractability.
{
"ranked_hypotheses": [
{
"title": "microglial priming as a partially upstream causal node rather than a pure disease-stage correlate requires proximal validation",
"description": "The debate supports carrying forward microglial priming as a partially upstream causal node rather than a pure disease-stage correlate only if a proximal endpoint changes before the late outcome. The decisive validation path is: triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses.",
"target_gene": "TREM2",
"dimension_scores": {
"evidence_strength": 0.57,
"novelty": 0.64,
"feasibility": 0.69,
"therapeutic_potential": 0.58,
"mechanistic_plausibility": 0.67,
"druggability": 0.5,
"safety_profile": 0.55,
"competitive_landscape": 0.55,
"data_availability": 0.63,
"reproducibility": 0.66
},
"composite_score": 0.604,
"evidence_for": [
{
"claim": "Analytic arms: cell-type-specific MR, scVelo trajectory, longitudinal CSF Granger causality. Exposure genes: TREM2, CX3CR1, C1QA, C1QB, C1QC. Diseases: AD, PD, ALS, MS.",
"source": "SDA-2026-04-28-microglial-priming-causal-nd"
}
],
"evidence_against": [
{
"claim": "microglial activation can be both cause and response; weak eQTL instruments, cell-state drift, and disease-stage confounding could inflate upstream causal estimates",
"source": "SDA-2026-04-28-microglial-priming-causal-nd"
}
]
},
{
"title": "Stratified falsifiers should govern Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference",
"description": "Claims from this analysis should be evaluated across TREM2, CX3CR1, C1QA, C1QB, C1QC; pooled effects are insufficient when causal direction, cell state, genotype, benchmark leakage, or reproducibility risks can dominate the result.",
"target_gene": "CX3CR1",
"dimension_scores": {
"evidence_strength": 0.54,
"novelty": 0.59,
"feasibility": 0.74,
"therapeutic_potential": 0.5,
"mechanistic_plausibility": 0.61,
"druggability": 0.43,
"safety_profile": 0.59,
"competitive_landscape": 0.53,
"data_availability": 0.68,
"reproducibility": 0.7
},
"composite_score": 0.591,
"evidence_for": [
{
"claim": "The analysis question names specific entities or evaluation structure.",
"source": "SDA-2026-04-28-microglial-priming-causal-nd"
}
],
"evidence_against": [
{
"claim": "The current record can still be confounded by stage, leakage, or artifact effects.",
"source": "SDA-2026-04-28-microglial-priming-causal-nd"
}
]
},
{
"title": "microglial priming across neurodegenerative diseases should remain under review until replicated",
"description": "The consensus is to preserve this as a debated candidate, not a canonical world-model claim. Replication or rerun evidence should precede promotion into Atlas or market funding.",
"target_gene": "C1QA",
"dimension_scores": {
"evidence_strength": 0.52,
"novelty": 0.55,
"feasibility": 0.71,
"therapeutic_potential": 0.52,
"mechanistic_plausibility": 0.58,
"druggability": 0.45,
"safety_profile": 0.58,
"competitive_landscape": 0.52,
"data_availability": 0.65,
"reproducibility": 0.69
},
"composite_score": 0.577,
"evidence_for": [
{
"claim": "Concrete next test: triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses",
"source": "SDA-2026-04-28-microglial-priming-causal-nd"
}
],
"evidence_against": [
{
"claim": "Promotion before replication would weaken quality control.",
"source": "SDA-2026-04-28-microglial-priming-causal-nd"
}
]
}
],
"knowledge_edges": [
{
"source_id": "SDA-2026-04-28-microglial-priming-causal-nd",
"source_type": "analysis",
"target_id": "TREM2",
"target_type": "entity",
"relation": "debate_context_supports_review_of"
},
{
"source_id": "SDA-2026-04-28-microglial-priming-causal-nd",
"source_type": "analysis",
"target_id": "CX3CR1",
"target_type": "entity",
"relation": "debate_context_supports_review_of"
},
{
"source_id": "SDA-2026-04-28-microglial-priming-causal-nd",
"source_type": "analysis",
"target_id": "C1QA",
"target_type": "entity",
"relation": "debate_context_supports_review_of"
},
{
"source_id": "SDA-2026-04-28-microglial-priming-causal-nd",
"source_type": "analysis",
"target_id": "C1QB",
"target_type": "entity",
"relation": "debate_context_supports_review_of"
}
],
"synthesis_summary": "Consensus: Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference is substantive enough for debate because it names microglial priming as a partially upstream causal node rather than a pure disease-stage correlate and can be tied to a concrete validation path: triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses. Dissent: microglial activation can be both cause and response; weak eQTL instruments, cell-state drift, and disease-stage confounding could inflate upstream causal estimates. The claim should remain under review until the falsifier or replication path is executed."
}